Respiree

Respiree is a digital health company that provides an all-inclusive cardio-pulmonary platform for remote patient monitoring and decentralized clinical trials. The company develops wireless biometric sensors and a SaaS platform that delivers real-time insights on patient vitals to practitioners, with AI-driven deterioration detection achieving greater than 90% accuracy days in advance of clinical events. Respiree offers two core solutions: Respiree Care, an end-to-end enterprise-connected remote-care solution spanning hospital-at-home, chronic disease management, and rehabilitation, featuring comprehensive lung-cardio biomarkers, cellular hubs for remote data acquisition, seamless EHR system integrations, and customizable alert systems to reduce readmissions and costs; and Respiree 1Bio, a decentralized clinical trials platform integrating thousands of pulmonary-cardio multi-modal biomarkers with clinically validated software for cost-effective drug development and novel therapeutic insights. The platform holds US FDA 510(k) clearance, CE approval, US patents, Australia TGA approval, HIPAA and FDA Cybersecurity certification, ISO 13485 QMS certification, and ISO 27001:2022 certification. Respiree serves healthcare systems, medical technology companies, biopharma, and patients across the care continuum, and has received the President's Technology Award 2024 and recognition as an ATS 2022 RIS Featured Start-up. Founded in 2018 and headquartered in Singapore, Respiree has raised $15.0M in Series A funding from investors including She1K, Oriza Holdings, SEEDS Capital, We Venture Capital, Clavystbio, Mayo Clinic, Greenwillow Capital Management, One Six 8 Ventures, Adaptive Capital Partners, Purpose Venture Capital, Startup Creasphere, Plug and Play APAC, and Luminon Technologies.

Wearable Technology > Health and Wellness Devices > Cardiac,

Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Cardiology > Wearable

College Wise > Nanyang Technological University (NTU)